ClinicaliQ Trial Snapshot
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma — Recruiting • Phase I • Oncology • NCT05650632.
- What is being tested: Etentamig (ABBV-383), an intravenously infused investigational agent, is being evaluated for safety and adverse events in adults with relapsed or refractory multiple myeloma—a blood cancer affecting plasma cells in bone marrow.
- Patient eligibility overview: The trial enrolls adult patients with multiple myeloma that has either recurred after initial treatment (relapsed) or failed to respond to previous therapies (refractory), representing a clinically challenging population with limited treatment options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug…
Eligibility Snapshot
- : * Must have measurable disease as outlined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.